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Abstract: Harmicines represent hybrid compounds composed of β-carboline alkaloid harmine and
cinnamic acid derivatives (CADs). In this paper we report the synthesis of amide-type harmicines
and the evaluation of their biological activity. N-harmicines 5a–f and O-harmicines 6a–h were
prepared by a straightforward synthetic procedure, from harmine-based amines and CADs using
standard coupling conditions, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b]pyridinium
3-oxid hexafluorophosphate (HATU) and N,N-diisopropylethylamine (DIEA). Amide-type harmicines
exerted remarkable activity against the erythrocytic stage of P. falciparum, in low submicromolar
concentrations, which was significantly more pronounced compared to their antiplasmodial activity
against the hepatic stages of P. berghei. Furthermore, a cytotoxicity assay against the human liver
hepatocellular carcinoma cell line (HepG2) revealed favorable selectivity indices of the most active
harmicines. Molecular dynamics simulations demonstrated the binding of ligands within the ATP
binding site of Pf Hsp90, while the calculated binding free energies confirmed higher activity of
N-harmicines 5 over their O-substituted analogues 6. Amino acids predominantly affecting the
binding were identified, which provided guidelines for the further derivatization of the harmine
framework towards more efficient agents.
Keywords: harmine; cinnamic acid; amide; antiplasmodial activity; Pf Hsp90; molecular dynamics
simulations; P. berghei; P. falciparum
1. Introduction
Malaria is a life-threatening parasitic disease that kills over 400,000 people each year, mainly
children under 5 years of age in sub-Saharan Africa [1]. Five species of Plasmodium cause malaria in
humans, and the most severe form of the disease is caused by P. falciparum, which is also the most
prevalent malaria parasite [2]. The complex life cycle of Plasmodium includes two hosts, Anopheles
mosquitoes and mammals. In the latter, a clinically silent phase of hepatic infection obligatorily
precedes a subsequent erythrocytic infection stage, responsible for the symptoms of malaria [3].
Since 2001, when the WHO recommended the use of artemisinin-based combination therapies (ACTs)
for treating P. falciparum malaria, ACTs have become the mainstay of malaria therapy due to their high
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efficacy, safety and lack of serious side effects [4]. Although malaria-caused deaths continuously drop
and several countries report either none or under 100 new cases each year, the rise of drug-resistant
parasites has slowed down that progress, especially in Asia. Failure rates of P. falciparum treatments
to the first-line ACTs were found to be above 10% in the Southeast Asia Region, and were as high as
93% in Thailand [1]. Despite numerous efforts to develop an effective vaccine against malaria, it still
remains out of reach [5–7]. Taken together, the rising number of drug-resistant parasite strains and the
unavailability of an effective vaccine exemplify the need to look for novel antimalarial agents.
Hybrid drugs, compounds with at least two distinct pharmacophores, represent one of the
possible strategies for finding novel biologically active molecules [8,9]. As previously shown by
us and others, the preparation of hybrids based on known antimalarial agents and cinnamic acid
(trans-3-phenyl-2-propenoic acid) or its derivatives (CAD) resulted in an increase in the former’s
in vitro antiplasmodial activity [10–15]. In our previous publication, we reported the synthesis and
biological activity of triazole-type harmicines, hybrids based on the alkaloid harmine and CAD,
linked via 1H-1,2,3-triazole (Figure 1) [15]. Harmine, a natural β-carboline alkaloid, was chosen as a
CAD partner due to its known in vitro and in vivo antiplasmodial activity [16,17]. We showed that
triazole-type harmicines exert a significant activity against both erythrocytic and hepatic stages of
Plasmodium infection. In addition, molecular dynamics (MD) simulations confirmed the binding of the
most active compound within the ATP binding site of P. falciparum heat shock protein 90 (Pf Hsp90) [15],
which is essential for the parasite’s development, and may play a major role in drug resistance [16–20].
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Since our earlier MD simulations did not identify the triazole ring as being crucial for binding
to Pf Hsp90 [15], we decided to simplify the linker between two main fragments, harmine and CAD.
To this end, triazole was replaced with its bioisostere, an amide bond, resulting in novel, amide-type
harmicines. Here, we report the synthesis of amide-type harmicines, their activity against both
erythrocytic and hepatic stages f Plasmodium infection, and their cytotoxicity. We also discuss how
binding to Pf Hsp90 affects their activity.
2. Results and Discussion
2.1. Chemistry
As a continuation of our work on hybrids based on harmin and CADs, we decid d to focus on
amide-type harmicines 5 and 6. Before synthesis, w evaluated the drug-like properties of the plann
compounds, by calculating relevant physico-chemical parameters included in the Lipinski’s rule of
five and Gelovani’s rules for small molecules, using Chemicalize.org software [21]. To our delight,
all compounds were in complete agreement with both sets of rules (Table S1).
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The chosen synthetic pathway towards novel harmicines involved three reaction steps, depicted
in Scheme 1. In the first step, harmine and harmole were alkylated with 2-(Boc-amino)ethyl bromide
to yield N- and O-alkylated compounds 1 and 2, respectively. The alkylation of harmine proceeded
smoothly with four equivalents of 2-(Boc-amino)ethyl bromide in the presence of four equivalents
of Cs2CO3, at 75 ◦C for 24 h, whereas employing the same reaction conditions for the alkylation of
harmole resulted in the formation of an N,O-bis alkylated product. A careful optimization of the
reaction conditions allowed the selective O-alkylation of harmole. Only traces of the N,O-bis alkylated
product were obtained when 2.6 equivalents of the alkylating agent and 1.35 equivalents of Cs2CO3
were employed at 110 ◦C for 4 h.
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The Boc-protecting group was efficiently removed under acidic conditions, to attain primary amines
3 and 4. In the final reaction step, the coupling between amines 3 or 4 and CADs was accomplished by
using sta dard coupling conditions, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b]pyridinium
3-oxid hexafluorophosphate (HATU) and N,N-diisopropylethylamine (DIEA) in dichloromethane (DCM).
The employed CADs were chosen according to the results of biological assays obtained earlier [15].
Coupling reactions were performed at room temperature, reaction times were short (1–2 h), and synthetic
yields were moderate to high (47–77%). Purification of the crude products by column chromatography
and/or crystallization was straightforward. Structures of the final products were confirmed by standard
spectroscopic/spectrometric methods (1H and 13C NMR, IR, MS), while their purity was assessed by
elemental analyses. The data obtained are provided in short in the Materials and Methods section, and in
detail in the Supplementary Information.
2.2. Biological Evaluations
2.2.1. Antiplasmodial Activity
After the successful preparation and characterization of the title compounds, we sought to assess
their in vitro activities against the erythrocytic and hepatic stages of Plasmodium infection and to
investigate whether they differ from those activities of the triazole-type harmicines reported earlier [15].
In Vitro Activity against P. falciparum Erythrocytic Stage
The in vitro antiplasmodial activity of harmicines against P. falciparum erythrocytic stage was
assessed employing both the chloroquine-sensitive (Pf 3D7) and the chloroquine-resistant (Pf Dd2)
strains, as previously described [22–24] (Table 1). Chloroquine and harmine were included as positive
controls in these assays, and the activity of amide-type harmicines was compared with that of the
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previously prepared triazole-type harmicines [15]. The conjugation of harmine to CADs yielded
compounds with significantly higher antiplasmodial activity against P. falciparum blood stages than the
parent compound, harmine. Remarkably, the activities were in the low submicromolar (Pf 3D7) and
submicromolar (Pf Dd2) concentrations, which is an activity one order of magnitude stronger than that
exerted by the triazole-type harmicines. To our surprise, and in contrast with the data obtained for
the triazole-type harmicines, analysis of the IC50 (concentration of the tested compound necessary for
50% growth inhibition) values for homologues N- and O-harmicines showed that the antiplasmodial
activity of N-harmicines 5 is significantly higher than that of O-harmicines 6 against both strains,
except in the case of compounds 5f and 6f (Pf 3D7), as well as 5c and 6c (Pf Dd2).
Table 1. In vitro screening of antiplasmodial activity of amide-type harmicines 5 and 6 against
erythrocytic stage of P. falciparum (Pf 3D7 and Pf Dd2 strains), cytotoxicity of human liver hepatocellular
carcinoma cell line (HepG2) and calculated selectivity indices. Data for harmine and chloroquine are
taken from [15].
Compd.
IC50 1 (µM)
SI 2
Pf3D7 PfDd2 HepG2
5a 0.49 ± 0.25 3 1.11 ± 0.15 3 350.31 ± 13.02 3 715
5b 0.07 ± 0.03 0.78 ± 0.32 54.11 ± 13.36 773
5c 0.07 ± 0.03 0.41 ± 0.01 2.88 ± 0.42 41
5d 0.09 ± 0.06 0.33 ± 0.11 20.99 ± 0.88 233
5e 0.04 ± 0.02 0.17 ± 0.01 2.91 ± 1.75 73
5f 0.26 ± 0.001 0.49 ± 0.24 74.69 ± 7.61 287
6a 0.98 ± 0.12 4.7 ± 2.65 12.74 ± 0.66 13
6b 2.75 ± 1.6 5.01 ± 0.83 12.86 ± 3.31 5
6c 0.37 ± 0.22 0.48 ± 0.28 6.11 ± 2.07 16
6d 0.15 ± 0.06 0.69 ± 0.18 7.63 ± 2.47 51
6e 0.32 ± 0.03 0.4 ± 0.24 7.72 ± 3.04 24
6f 0.21 ± 0.14 1.09 ± 0.49 10.53 ± 0.43 50
6g 0.93 ± 0.28 3.92 ± 1.35 16.17 ± 1.86 17
6h 6.78 ± 0.72 19.53 ± 11.83 61.28 ± 2.75 9
CQ 4 0.003 ± 0.002 0.20 ± 0.10 n.d. n.d.
Harmine 8.25 ± 2.83 >27.7 > 250 30
1 IC50, the concentration of the tested compound necessary for 50% growth inhibition. 2 SI, selectivity index, ratio
between IC50 (HepG2) and IC50 (Pf 3D7). 3 Results represent mean ± SD, n > 2. 4 CQ, chloroquine.
We further compared the IC50 values within both series and found that the effects of the substituents
in the cinnamic scaffold on the antiplasmodial activity were more pronounced for the Pf 3D7 strain.
As shown in Table 1, N-harmicines bearing halogens either in the p- or the m-positions (5b–e)
exhibited significantly higher activities than unsubstituted and p-methoxy substituted compounds.
In the O-harmicines 6 series, a substitution in the p-position was preferred, regardless of the type
of substituent. Interestingly, the substitution of hydrogen with its isostere fluorine in the p-position
yielded the most active compound among O-harmicines (6d), while the same substitution in the
m-position resulted in decreased activity. The replacement of hydrogen with fluorine in the o-position
had no significant influence on the antiplasmodial activity. Conversely, the substitution of the hydrogen
with a methyl group in the α-position yielded compound 6h, with at least one order of magnitude
weaker antiplasmodial activity than other O-harmicines. The influence of lipophilicity was estimated
by the comparison of IC50 and calculated log P values (Table S1). More lipophilic N-harmicines exerted
more pronounced activity, while O-harmicines did not follow the same pattern. The most active
compound against both strains was N-harmicine 5e (IC50(Pf 3D7) = 0.04 µM, IC50(Pf Dd2) = 0.17 µM).
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In Vitro Activity against P. berghei Hepatic Stages
The in vitro activity of harmicines against the hepatic stages of Plasmodium infection was evaluated
by employing rodent P. berghei parasites and a human hepatoma cell line (Huh7), as previously
described [25,26]. Each compound was assessed at 1 and 10 µM (Figure 2), with harmine and DMSO
serving as positive and negative controls, respectively. Concomitantly, the compounds’ cytotoxicity to
Huh7 cells was assessed by cell confluency measurement. The results obtained show that amide-type
harmicines do not exert significant activity against the hepatic stages of P. berghei infection. The compounds’
activity at 1 µM is similar to that of the parent compound harmine, but they are significantly more active
than the latter at 10 µM. The marked cytotoxicity observed to Huh7 cells, even at 1 µM, precluded the
determination of IC50 values for the compounds’ hepatic stages antiplasmodial activity.
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Figure 2. In vitro activity against P. berghei liver stages of har icines 5a–f and 6a–h at 1 and 10 µ
concentrations. Total parasite load (infection scale, bars) and cell viability (cell confluency scale, dots)
are shown. Results were normalized to the negative control, DMSO, and are represented as mean ± SD,
n = 1.
2.2.2. Cytotoxicity Assay
A cytotoxicity assay was performed using the neutral red assay, as described previously, against
human liver hepatocellular carcinoma cell line (HepG2) [27] (Table 1). For the safety assessment,
a selectivity index (SI) for each compound was calculated as the fractional ratio between the IC50
values for HepG2 and P. falciparum Pf 3D7 strain (Table 2). In general, N-harmicines 5 are less cytotoxic
than O-harmicines 6, which is in agreement with the results obtained for triazole-type harmicines.
Furthermore, all N-harmicines, but only two O-harmicines, 6d and 6f, have more favorable SIs than
the parent compound harmine (SI = 30). A close inspection of the IC50 values within the series of
N-harmicines revealed that substitution of hydrogen in the cinnamic moiety by F, Cl or Br led to a
significant increase in cytotoxicity (H < F < Cl ≈ Br). O-harmicines showed similar levels of cytotoxicity,
independently of the cinnamic substituent. Compound 6h, with a methyl group in the α-position in
the CAD region, was the only exception, as it was significantly less toxic than the other O-harmicines.
Compound 5b, with a m-fluorine substituent in the cinnamic scaffold, exerted the highest selectivity
(SI = 773), followed by 5a, an amide with unsubstituted cinnamic acid (SI = 715). Two other compounds,
namely 5f and 5d, also showed pronounced selectivity (SIs 287 and 233, respectively), whereas 6h and
6b displayed low selectivity (SIs 9 and 5, respectively).
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Table 2. Calculated total binding free energies (∆GBIND) from molecular dynamics trajectories using
MM-GBSA approach, and their decomposition on a per-residue basis for selected derivatives. 1 Data for
harmines are taken from [15].
Residue 5a 5d 5e 6a 6d 6e Harmine
Asn37 −1.82 −1.33 −2.01 −2.09 −1.69 −1.81 0.00
Asp79 1.47 1.36 1.58 1.11 1.30 0.74 0.00
Arg98 −0.05 −0.93 −1.39 −2.00 −2.45 −2.24 0.00
Phe124 −1.44 −1.68 −0.64 −0.58 −0.35 −0.37 0.00
Met84 −2.50 −2.63 −2.70 −2.05 −2.25 −2.02 0.00
Gly83 −0.79 −1.28 −1.63 −1.00 −1.69 −1.56 0.00
Ile82 −0.88 −1.50 −1.51 −1.28 −1.49 −1.43 0.00
Thr171 −1.60 −1.92 −1.51 −0.74 −0.51 −0.53 0.00
Ala41 −1.39 −1.37 −1.44 −1.32 −1.40 −1.27 0.00
Ile173 −1.05 −1.13 −1.18 −0.46 −0.42 −0.32 −0.01
Asn92 −0.96 −0.94 −1.06 −1.64 −1.43 −1.41 0.00
Ala38 −0.90 −0.91 −0.89 −0.56 −0.53 −0.50 0.00
Leu93 −0.63 −0.60 −0.80 −0.46 −0.52 −0.59 0.00
Leu34 −0.68 −0.82 −0.75 −0.16 −0.14 −0.12 0.00
Val136 −0.67 −0.72 −0.64 −0.11 −0.14 −0.12 −0.02
Gly81 −0.33 −0.49 −0.54 −0.37 −0.42 −0.35 0.00
Thr95 0.03 0.03 0.03 0.03 0.04 0.04 0.00
Asp142 0.04 0.03 0.04 0.03 0.03 0.03 0.00
Glu48 0.03 0.05 0.04 0.05 0.06 0.06 0.00
Total
∆GBIND
−33.9 −38.1 −40.9 −34.6 −35.7 −37.5 −7.5
1 Residues are selected to list those identified as belonging to the ATP binding pocket (Asn37, Asp79, Arg98, Phe124)
and all of those with contributions higher than −0.50 and lower than 0.03 kcal mol−1 to the most potent 5e. All values
are in kcal mol−1.
2.3. Molecular Dynamics Simulations
Computational analysis was performed to gain an insight into the binding of a representative
set of ligands, involving both N-substituted (5a, 5d and 5e) and O-substituted derivatives (6a, 6d and
6e), and to interpret their observed affinities towards Pf Hsp90. To this end, MD simulations were
employed to obtain the binding poses and the accompanying binding free energies, as well as to
identify residues governing the binding. These results were compared with those previously obtained
for the parent harmine [15].
We calculated the selected compounds’ binding free energies (∆GBIND), as well as their
decomposition into contributions from individual residues (Table 2). The specific residues considered
for the analysis include those responsible for the binding of 5e within the ATP binding pocket (Asn37,
Asp79, Arg98, Phe124) [28,29], and all those with contributions higher than −0.50 and lower than
0.03 kcal mol−1, leading to the identification of the residues that are the most and the least responsible
for the binding of 5e to Pf Hsp90.
Our data reveal that all evaluated compounds are associated with negative ∆GBIND, in agreement
with their high antiplasmodial activity. In addition, a very good agreement between calculated data
and experimentally measured activities is observed. Firstly, with the highest binding free energy of
∆GBIND = −40.9 kcal mol−1, computations clearly predict 5e to have the highest activity, which was
confirmed experimentally. It is worth noting that this value exceeds that of an analogous triazole-based
N-substituted derivative studied earlier [15], where the computed value was −39.0 kcal mol−1, being
strongly in line with a general tendency of a higher activity for the amide-based derivatives examined
here. Moreover, the calculated difference of −1.9 kcal mol−1 nicely agrees with a trend in the matching
IC50(Pf 3D7) activities of 0.04 µM for 5e and 0.44 µM for its triazole-based analogue [15], which predicts
a difference of ∆∆GBIND = −1.6 kcal mol−1. Secondly, computed values evidently distinguish between
O-substituted and N-substituted derivatives, with the latter group involving better binders amid the
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two families. Lastly, among each set, the calculated ∆GBIND values indicate identical binding trends
regarding the substituents introduced, which assume p-Cl (5e) > p-F (5d) > p-H (5a), in the same way
as the matching O-substituted derivatives 6e > 6d > 6a. With this in mind, we can safely conclude
that the excellent agreement between computations and experiments lends strong credence to the
computational methodology employed.
The calculated ∆GBIND value for 5e is the most exergonic, suggesting it is optimally positioned
within Pf Hsp90. Its decomposition into contributions from specific residues reveals that 5e is clearly
positioned within the ATP binding site, as its binding is dominated by residues that define this
cavity (Figure 3). This holds in particular for Asn37 and Arg98, where the contributions obtained are
−2.01 and −1.39 kcal mol−1, respectively, closely followed by Phe124, where it is −0.64 kcal mol−1.
The corresponding MD trajectories show that the tricyclic aromatic ring and the attached –OMe group
on 5e are responsible for these favorable contributions. Specifically, side chains of both Asn37 and
Phe124 are located above the aromatic framework of 5e, forming positive N–H···π and π···π stacking
interactions, respectively, while Arg98 uses its cationic guanidine moiety to donate hydrogen bonding
to the ligand’s methoxy oxygen. The overall effect of these three residues is somewhat reduced by
the unfavorable effect of Asp79, which is overcome by the contribution of several other residues that
promote the binding (Table 2), and which are positioned close to the ATP binding site. The reason
behind the negative contribution of Asp79 lies in the repulsion between its carboxylic moiety and the
–CH2–CH2– linker in 5e connecting the amide substituent with the harmine N-position. This might
suggest that the parent harmine, containing all of the positively contributing structural elements—both
the tricyclic ring and the –OMe group—while being deprived of the mentioned linker, let alone having
the acidic N–H instead that could engage in favorable interactions with Asp79, would represent a
much better binder than 5e. However, quite the opposite occurs, as harmine reveals very poor binding
properties, displaying a significantly lower ∆GBIND (−7.5 kcal mol−1) (Table 2), consistent with the
significantly higher IC50 value of 8.25 µM (Table 1). Moreover, although the relationship between IC50
and ∆GBIND values is not so straightforward, the IC50 value measured for harmine roughly translates to
a binding energy of −6.9 kcal mol−1, which again confirms the validity of our computational setup and
nicely ties into our computational and experimental results. Additionally, the data shown in Table 2
clearly indicate that, aside from a very low ∆GBIND value, harmine binds even outside the ATP binding
pocket (Figure 3), as none of the residues either defining it or close to it are contributing to the binding.
All of these observations underline the importance of the N-site of harmine for the inactivation of
Pf Hsp90, and justify the synthetic strategy employed here, as carefully tailored N-substituents can
overcome unfavorable interactions with the anionic Asp79 through their positive interactions with
the rest of the protein. This valuable insight might provide precious information for further harmine
derivatization. Lastly, besides the ATP binding site residues mentioned above, the binding of 5e
is particularly promoted by Met84, which uses its –SMe side chain to form the stabilizing C–H···π
interactions with the aromatic unit in 5e (Figure 3), thus allowing for the highest individual contribution
among all amino acid residues.
Interestingly, although N-derivatives 5 with different para-groups exhibit different antiplasmodial
activities (Table 1), we did not observe any significant interactions between moieties placed at this
position and the protein (Figure 3). Instead, this site points outside the Pf Hsp90. Thus, it is presently
unclear what the immediate effect of this position for the ligand affinity is, and how to eventually
advance the binding properties with such further substitutions. Still, the extent of this effect is modest
and is likely channeled through electron-donating or electron-accepting features of the introduced
substituent that modulate the electron density throughout each derivative, which, in turn, affect its
interactions with the protein. This conclusion is justified by the data in Table 1, considering that all six
N-derivatives stretch over only one order of magnitude in the affinities measured, from 0.49 µM in 5a
to 0.04 µM in 5e, thus confirming only a minor effect of the introduced para-substituent. Therefore,
it is unlikely that a potential insertion of additional para-moieties in 5 will considerably improve the
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compounds’ activity. Instead, redesigning the employed –CH2–CH2– linker emerges as a promising
strategy that will be exploited in our future work.
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  Figure 3. Binding positions of ligands 5e (in blue) and 6a (in yellow) within the ATP binding site in
Pf Hsp90 and harmine (in red) outside of it (left). The interaction of 5e (top right) and 6a (bottom right)
with the relevant binding site residues.
Replacing p-Cl (5e) with p-F (5d) decreases the IC50 value by a factor of two and is supported by
the 2.8 kcal mol−1 lower binding energy of ∆GBIND(5d) =−38.1 kcal mol−1. In 5d, reduced contributions
from the ATP binding site residues are observed, which suggests a slight change in the binding pose,
except for Phe124, which benefits from the modified ligand’s positions by gaining a full kcal mol−1
relative to 5e, as a result of the more optimized π···π stacking interactions in that case. Lastly, complete
removal either of the para-halogens, as in 5a, yields a further reduction in both IC50 and ∆GBIND values
and results in a slightly changed binding pose. The latter appears enough to position the –OMe group
away from Arg98, leading to a significant reduction in its binding contribution, while lowering the
impact of other residues as well. Given the lowest affinity of 5a among all N-derivatives, these results
suggest the predominant role of the introduced para-substituent through tuning the position of ligands
within the binding site, thus allowing for the optimization of ligand contacts with the protein residues.
Derivatives 6 have a functionalized harmine –OMe group, while maintaining the unsubstituted
secondary amine on the central aromatic ring. In line with the above, this is immediately evident
in diminishing the negative contribution of Asp79 from 1.58 kcal mol−1 in 5e to 1.11, 1.30 and even
0.74 kcal mol−1 in 6a, 6d and 6e, respectively. Yet, these highly positive values do not indicate any
favorable hydrogen bonding among Asp79 carboxylate and the ligands amino group, which was
also not observed in our simulations. On the other hand, derivatives 6 are also positioned within
the ATP binding site in Pf Hsp90, but in a way which does not allow for an efficient interaction with
Asp79 (Figure 3). This change in the binding pose is evident in the increase in the contribution of
Arg98, which moves from forming hydrogen bonding with the ligand’s methoxy oxygen, as in 5,
into forming cation···π interactions with aromatic fragments in the O-substituted derivatives 6 that
turned out as even more favorable (Table 2). The latter also allows Asn92 to optimize its N–H···π
interactions with systems 6, evident in its increased contributions. Other than those, in general, most
of the ATP binding site residues and those in their vicinity have reduced contributions relative to the
analogous systems 5, ultimately leading to the lower activities observed for the matching O-substituted
derivatives 6. A likely reason for that is the observed tendency of these systems to assume geometries
that enable the intramolecular C–H···π stacking interactions among aromatic fragments within the
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ligands 6 themselves (Figure 3), which diminish a number of potential contacts with the protein.
Additionally, data in Table 2 shows a significant drop in the individual contributions of Thr171, Ile173,
Leu34 and Val136, which are considerably lower in 6 than in 5. These residues form a hydrophobic
pocket around the unsubstituted –OMe group and vicinal fragments in 5, thus promoting the binding,
which is not possible upon substituting this part in systems 6, thus explaining the lower affinities of
the latter. Overall, this indicates that the O-site in the harmine derivatives provides fewer promising
opportunities for the synthesis of successful Pf Hsp90 binders, in agreement with our experimental data.
3. Materials and Methods
3.1. Chemistry
3.1.1. General Information
Melting points were determined on a Stuart Melting Point Apparatus (Barloworld Scientific,
England, UK) in open capillaries and were uncorrected. FTIR-ATR spectra were recorded using
a Fourier-Transform Infrared Attenuated Total Reflection UATR Two Spectrometer (PerkinElmer,
Waltham, MA, USA) in the range from 450 to 4000 cm−1. 1H and 13C NMR spectra were recorded
on a Bruker Avance III HD operating at 300 or 400 MHz for the 1H and 75, 101 or 151 MHz for the
13C nuclei (Bruker, Billerica, MA, USA). Samples were measured in DMSO-d6 solutions at 20 ◦C in
5 mm NMR tubes. Chemical shifts (δ) are reported in parts per million (ppm) using tetramethylsilane
(TMS) as a reference in the 1H and DMSO residual peak as a reference in the 13C spectra (39.51 ppm).
Coupling constants (J) are reported in hertz (Hz). Mass spectra were recorded on HPLC-MS/MS
(HPLC, Agilent Technologies 1200 Series; MS, Agilent Technologies 6410 Triple Quad, San Jose, CA,
USA). Mass determination was performed using electrospray ionization (ESI) in a positive mode.
Elemental analyses were performed on a CHNS LECO analyzer (LECO Corporation, St. Joseph,
MI, USA). Analyses indicated by the symbols of the elements were within ±0.4% of their theoretical
values. Microwave-assisted reactions were performed in a microwave reactor CEM Discover (CEM,
Matthews, NC, USA) in a glass reaction vessel. All compounds were routinely checked by TLC
with silica gel 60F-254 glass plates (Merck KGaA, Darmstadt, Germany) using DCM/methanol 8:1
and 85:15 as the solvent system. Spots were visualized by short-wave UV light (λ = 254 nm) and
iodine vapor. Column chromatography was performed on silica gel 0.063–0.200 mm (Sigma-Aldrich,
St. Louis, MO, USA) with the same eluents used for TLC. All chemicals and solvents were of analytical
grade and purchased from commercial sources. CADs were purchased as predominantly trans
stereoisomers (≥99%). Harmine, acetic acid, hydrochloric acid, cinnamic acid, α-methylcinnamic acid,
2-fluorocinnamic acid, 3-fluorocinnamic acid, 4-fluorocinnamic acid, 4-methoxycinnamic acid and
4-chlorocinnamic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cesium carbonate,
2-(Boc-amino)ethyl bromide, HATU and 3-bromocinnamic acid were purchased from TCI Chemicals
(Tokyo, Japan). Hydrobromic acid (47%) was purchased from Merck (Darmstadt, Germany), DIEA
from Alfa Aesar (Kandel, Germany), DCM from Fischer Scientific (Waltham, MA, USA), diethyl ether
from ITW Reagents (Darmstadt, Germany), anhydrous sodium sulphate from Gram-Mol (Zagreb,
Croatia) and N,N-dimethylformamide (DMF) from Kemika (Zagreb, Croatia). Harmole was prepared
according to the modified literature procedure for harmine using HBr/glacial acetic acid mixture, under
MW irradiation [30].
3.1.2. Synthesis of tert-butyl (2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)ethyl)carbamate (1)
To a stirred solution of harmine (0.200 g, 0.94 mmol) in anhydrous DMF (3 mL) at 75 ◦C under an
argon atmosphere, Cs2CO3 (1.228 g, 3.77 mmol, 4 equivalents) was added. The resulting suspension
was stirred at 75 ◦C for 20 min, followed by the addition of 2-(Boc-amino)ethyl bromide (0.844 g,
3.77 mmol, 4 equivalents). The reaction mixture was stirred at 75 ◦C for 24 h, cooled down, poured into
H2O (40 mL) and extracted with ethyl acetate (3 × 40 mL). The collected organic layers were washed
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with H2O, dried over anhydrous sodium sulfate, filtered, and evaporated under the reduced pressure.
After purification by column chromatography (DCM:MeOH = 8:1) and trituration with diethyl ether,
0.195 g (58%) of 1 was obtained; mp 197.5–199 ◦C; IR (ATR, ν/cm−1) 3183, 3065, 3013, 2993, 2969, 2937,
1701, 1623, 1567, 1502, 1447, 1409, 1366, 1343, 1330, 1313, 1278, 1247, 1195, 1166, 1146, 1124, 1092,
1048, 1018, 970, 944, 876, 841, 803, 768, 727, 684, 639, 598, 559, 534; 1H NMR (DMSO-d6) δ 8.15 (d, 1H,
J = 5.1 Hz), 8.07 (d, 1H, J = 8.5 Hz), 7.85 (d, 1H, J = 5.0 Hz), 7.22 (s, 1H), 7.02 (t, 1H, J = 5.2 Hz), 6.87 (dd,
1H, J = 8.4, 1.6 Hz), 4.55 (t, 2H, J = 6.6 Hz), 3.92 (s, 3H), 3.33–3.31 (m, 2H), 2.95 (s, 3H), 1.29 (s, 8H),
1.01 (s, 1H); 13C NMR (DMSO-d6) δ 160.45, 155.62, 142.84, 140.46, 137.63, 134.70, 128.39, 122.20, 114.35,
112.10, 108.95, 93.80, 77.77, 55.47, 43.98, 39.97, 28.01, 22.99; ESI-MS: m/z 356.2 (M + 1)+.
3.1.3. Synthesis of tert-butyl (2-((1-methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethyl)carbamate (2)
To a stirred solution of harmole (0.257 g, 1.30 mmol) in anhydrous DMF (3 mL), under an argon
atmosphere, Cs2CO3 (0.570 g, 1.75 mmol, 1.35 equivalents) was added. The resulting suspension
was stirred at room temperature for 20 min, followed by the addition of 2-(Boc-amino)ethyl bromide
(0.755 g, 3.37 mmol, 2.6 equivalents). The reaction mixture was stirred at 110 ◦C for 4 h, cooled down,
poured into H2O (30 mL) and extracted with ethyl acetate (3 × 40 mL). The collected organic layers
were washed with H2O, dried over anhydrous sodium sulfate, filtered, and evaporated under the
reduced pressure. After purification by column chromatography (DCM:MeOH = 8:1) and trituration
with diethyl ether, 0.278 g (63%) of 2 was obtained; mp 189.5–190.5 ◦C; IR (ATR, ν/cm−1) 3380, 3134,
3052, 2978, 2944, 2872, 2764, 2726, 2582, 2406, 1692, 1634, 1568, 1530, 1480, 1448, 1394, 1368, 1334, 1296,
1260, 1174, 1114, 1052, 1010, 964, 872, 846, 820, 788, 720, 686, 634, 604, 522; 1H NMR (DMSO-d6) δ 11.42
(s, 1H), 8.15 (d, 1H, J = 5.3 Hz), 8.05 (d, 1H, J = 8.6 Hz), 7.81 (d, 1H, J = 5.3 Hz), 7.06 (t, 1H, J = 5.4 Hz),
7.00 (d, 1H, J = 2.1 Hz), 6.85 (dd, 1H, J = 8.7, 2.2 Hz), 4.08 (t, 2H, J = 5.8 Hz), 3.41–3.35 (m, 2H), 2.73 (s,
3H), 1.40 (s, 9H); 13C NMR (DMSO-d6) δ 159.21, 155.72, 141.91, 141.20, 137.58, 134.54, 127.25, 122.65,
114.95, 111.95, 109.32, 95.38, 77.79, 66.65, 28.22, 20.25; ESI-MS: m/z 342.3 (M + 1)+.
3.1.4. General Procedure for the Synthesis of Amines 3 and 4
A solution of the corresponding compound 1 or 2 (0.70 mmol) and 1.76 mL 4 M HCl (7 mmol)
in MeOH (4 mL) was stirred at 50 ◦C for 16 h (compound 1) or 2 h (compound 2). Upon completion,
solvent was removed under the reduced pressure. The residue was dissolved in H2O (20 mL), basified
to pH 12 with 5% NaOH, and extracted with ethyl acetate (5 × 40 mL). The collected organic layers were
dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. The crude
product was triturated with diethyl ether.
2-(7-Methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)ethan-1-amine (3)
Yield: 0.179 g, (76%); mp 133.5–135.5 ◦C; IR (ATR, ν/cm−1); 3354, 3327, 3274, 3054, 3039, 2966, 2932,
2837, 1751, 1621, 1563, 1496, 1443, 1404, 1343, 1302, 1283, 1236, 1219, 1151, 1136, 1117, 1089, 1040, 1021,
973, 941, 922, 887, 848, 815, 768, 723, 643, 599, 551, 528; 1H NMR (DMSO-d6) δ 8.16 (d, 1H, J = 5.2 Hz),
8.07 (d, 1H, J = 8.6 Hz), 7.86 (d, 1H, J = 5.2 Hz), 7.24 (d, 1H, J = 2.1 Hz), 6.87 (dd, 1H, J = 8.6, 2.2 Hz),
4.54 (t, 2H, J = 7.3 Hz), 3.91 (s, 3H), 2.97 (s, 3H), 2.93 (t, 2H, 2’, J = 7.3 Hz); 13C NMR (DMSO-d6) δ
160.51, 142.95, 140.67, 137.64, 134.79, 128.22, 122.33, 114.17, 112.23, 109.14, 93.79, 55.63, 47.15, 42.11,
23.33; ESI-MS: m/z 256.3 (M + 1)+.
2-((1-Methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethan-1-amine (4)
Yield: 0.169 g, (66%); mp 172.5–173 ◦C; IR (ATR, ν/cm−1) 3954, 3908, 3838, 3786, 3716, 3656, 3530, 3394,
3332, 3250, 3156, 3068, 2930, 2864,2774, 2372, 1892, 1756, 1720, 1628, 1568, 1486, 1444, 1326, 1284, 1238,
1180, 1104, 1028, 996, 908, 860, 812, 636, 590; 1H NMR (DMSO-d6) δ 11.38 (s, 1H), 8.15 (d, 1H, J = 5.3 Hz),
8.04 (d, 1H, J = 8.6 Hz), 7.79 (d, 1H, J = 5.3 Hz), 7.01 (d, 1H, J = 2.2 Hz), 6.85 (dd, 1H, J = 8.6, 2.2 Hz),
4.03 (t, 2H, J = 5.7 Hz), 2.95 (t, 2H, J = 5.7 Hz), 2.73 (s, 3H), 1.57 (s, 2H); 13C NMR (DMSO-d6) δ 159.47,
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141.90, 141.23, 137.73, 134.53, 127.19, 122.57, 114.82, 111.89, 109.37, 95.27, 70.46, 41.02, 20.32; ESI-MS: m/z
242.2 (M + 1)+.
3.1.5. General Procedure for the Synthesis of Harmicines 5a–f
A solution of CAD (0.18 mmol), DIEA (0.061 mL, 0.35 mmol) and HATU (0.067 g, 0.18 mmol) in
DCM (3 mL) was stirred at room temperature for 15 min, followed by the addition of amine 3 (0.045 g,
0.18 mmol). The resulting solution was stirred at room temperature for 2 h. Purification was performed
by either Method A or Method B.
Method A: The reaction mixture was extracted with brine (2 × 20 mL) and water (1 × 20 mL).
The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under the reduced
pressure. The crude product was purified by column chromatography (DCM:MeOH = 8:1) and
triturated with diethyl ether.
Method B: The resulting precipitate was filtered off. The mother liquor was extracted with brine
(2 × 20 mL) and water (1 × 20 mL). The organic layer was dried over anhydrous sodium sulfate, filtered,
evaporated under the reduced pressure and residue combined with the filtered precipitate. The crude
product was purified by column chromatography (DCM:MeOH = 8:1) and triturated with diethyl ether.
N-(2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)ethyl)cinnamamide (5a)
CAD: 0.026 g of trans-cinnamic acid; purification: Method A; yield: 0.034 g, (51%); mp 201.5–203 ◦C;
IR (ATR, ν/cm−1) 3202, 3027, 2968, 2926, 2852, 1672, 1622, 1566, 1532, 1496, 1447, 1405, 1340, 1306,
1282, 1247, 1218, 1196, 1175, 1138, 1091, 1043, 1020, 972, 938, 856, 814, 762, 679, 641, 597, 555, 485;
1H NMR (DMSO-d6) δ 8.41 (t, 1H, J = 5.9 Hz), 8.18 (d, 1H, J = 5.2 Hz), 8.09 (d, 1H, J = 8.6 Hz), 7.88
(d, 1H, J = 5.2 Hz), 7.57–7.55 (m, 2H), 7.48–7.36 (m, 4H), 7.27 (d, 1H, J = 1.9 Hz), 6.87 (dd, 1H, J = 8.6,
2.0 Hz), 6.54 (d, 1H, J = 15.8 Hz), 4.67 (t, 2H, J = 6.8 Hz), 3.90 (s, 3H), 3.59 (q, 2H, J = 6.5 Hz), 2.99 (s,
3H); 13C NMR (DMSO-d6) δ 165.72, 160.49, 142.90, 140.64, 139.16, 137.85, 134.74, 134.64, 129.56, 128.94,
128.46, 127.57, 122.37, 121.65, 114.27, 112.25, 109.40, 93.49, 55.38, 43.36, 39.10, 23.09; ESI-MS: m/z 386.4
(M + 1)+; Anal. Calcd. for C24H23N3O2: C, 74.78; H, 6.01; N, 10.90, found: C, 74.88; H, 6.21; N, 10.75.
(E)-3-(3-fluorophenyl)-N-(2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)ethyl)acrylamide (5b)
CAD: 0.029 g of 3-fluorocinnamic acid; purification: Method A; yield: 0.033 g, (47%); mp 226.5–228 ◦C;
IR (ATR, ν/cm−1); 3661, 3599, 3182, 3009, 2931, 2838, 1671, 1623, 1584, 1538, 1505, 1445, 1412, 1343, 1295,
1240, 1182, 1141, 1095, 1043, 1017, 976, 848, 808, 783, 729, 668, 556, 517; 1H NMR (DMSO-d6) δ 8.42 (t,
1H, J = 5.9 Hz), 8.18 (d, 1H, J = 5.2 Hz), 8.09 (d, 1H, J = 8.6 Hz), 7.89 (d, 1H, J = 5.2 Hz), 7.49–7.39 (m,
4H), 7.27 (d, 1H, J = 2.0 Hz), 7.25–7.18 (m, 1H), 6.87 (dd, 1H, J = 8.6, 2.1 Hz), 6.59 (d, 1H, J = 15.8 Hz),
4.67 (t, 2H, J = 6.9 Hz), 3.90 (s, 3H), 3.59 (q, 2H, J = 6.5 Hz), 2.99 (s, 3H); 13C NMR (DMSO-d6) δ 165.44,
162.45 (d, J = 243.8 Hz), 160.51, 142.91, 140.62, 137.89, 137.80, 137.35 (d, J = 7.9 Hz), 134.63, 130.90 (d,
J = 8.4 Hz), 128.50, 123.76, 123.20, 122.40, 116.23 (d, J = 21.3 Hz), 114.28, 113.97 (d, J = 21.8 Hz), 112.27,
109.40, 93.51, 55.39, 43.33, 39.10, 23.05; ESI-MS: m/z 404.4 (M + 1)+; Anal. Calcd. for C24H22FN3O2: C,
71.45; H, 5.50; N, 10.42, found: C, 71.26; H, 5.79; N, 10.59.
(E)-3-(3-bromophenyl)-N-(2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)ethyl)acrylamide (5c)
CAD: 0.040 g of 3-bromocinnamic acid; purification: Method B; yield: 0.057 g, (70%); mp 225–226 ◦C;
IR (ATR, ν/cm−1); 3180, 3051, 3021, 2975, 2932, 2901, 2864, 2792, 2559, 1944, 1875, 1679, 1621, 1565, 1498,
1468, 1450, 1410, 1377, 1345, 1305, 1251, 1223, 1195, 1138, 1106, 1043, 1018, 980, 941, 911, 885, 862, 812,
786, 729, 671, 648, 614, 599, 555, 537, 515; 1H NMR (DMSO-d6) δ 8.39 (t, 1H, J = 6.0 Hz), 8.18 (d, 1H,
J = 5.2 Hz), 8.09 (d, 1H, J = 8.6 Hz), 7.89 (d, 1H, J = 5.2 Hz), 7.77 (t, 1H, J = 1.7 Hz), 7.57 (dd, 2H, J = 8.1,
1.4 Hz), 7.44–7.35 (m, 2H), 7.26 (d, 1H, J = 2.1 Hz), 6.87 (dd, 1H, J = 8.6, 2.2 Hz), 6.59 (d, 1H, J = 15.8 Hz),
4.67 (t, 2H, J = 6.9 Hz), 3.90 (s, 3H), 3.60 (q, 2H, J = 6.5 Hz), 2.99 (s, 3H); 13C NMR (DMSO-d6) 165.39,
160.52, 142.92, 140.62, 137.80, 137.57, 137.33, 134.64, 132.09, 131.04, 130.13, 128.52, 126.43, 123.32, 122.41,
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122.27, 114.29, 112.29, 109.39, 93.54, 55.41, 43.34, 39.10, 23.05; ESI-MS: m/z, 464.3 (M + 1)+, 466.3 (M + 1)+;
Anal. Calcd. for C24H22BrN3O2: C, 62.08; H, 4.78; N, 9.05, found: C, 62.31; H, 4.89; N, 9.27.
(E)-3-(4-fluorophenyl)-N-(2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)ethyl)acrylamide (5d)
CAD: 0.029 g of 4-fluorocinnamic acid; purification: Method B; yield: 0.042 g, (57%); mp 202.5–204 ◦C;
IR (ATR, ν/cm−1); 3664, 3583, 3438, 3207, 3083, 2985, 2938, 2756, 2723, 1656, 1622, 1601, 1545, 1508, 1471,
1449, 1416, 1390, 1370, 1345, 1292, 1256, 1223, 1203, 1181, 1163, 1141, 1098, 1045, 1018, 976, 944, 836,
741, 722, 644, 557, 530, 511; 1H NMR (DMSO-d6) δ 8.40 (s, 1H), 8.19 (d, 1H, J = 4.3 Hz), 8.11 (d, 1H,
J = 8.4 Hz), 7.92 (d, 1H, J = 4.2 Hz), 7.62 (t, 2H, J = 6.6 Hz), 7.45 (d, 1H, J = 15.7 Hz), 7.28–7.23 (m,
3H), 6.88 (d, 1H, J = 8.0 Hz), 6.49 (d, 1H, J = 15.7 Hz), 4.67 (t, 2H, J = 6.7 Hz), 3.90 (s, 3H), 3.59 (q, 2H,
J = 6.8 Hz), 3.00 (s, 3H); 13C NMR (DMSO-d6) δ 165.69, 162.76 (d, J = 247.0 Hz), 160.67, 143.12, 140.44,
138.01, 137.34, 134.59, 131.38 (d, J = 2.5 Hz), 129.77 (d, J = 8.3 Hz), 128.78, 122.52, 121.53, 115.93 (d,
J = 21.7 Hz), 114.22, 112.40, 109.62, 93.52, 55.44, 43.40, 39.09, 22.76; ESI-MS: m/z 404.2 (M + 1)+; Anal.
Calcd. for C24H22FN3O2: C, 71.45; H, 5.50; N, 10.42, found: C, 71.58; H, 5.37; N, 10.48.
(E)-3-(4-chlorophenyl)-N-(2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)ethyl)acrylamide (5e)
CAD: 0.032 g of 4-chlorocinnamic acid; purification: Method B; yield: 0.039 g, (53%); mp 245 ◦C
(decomp.); IR (ATR, ν/cm−1) 3195, 3103, 3025, 2998, 2928, 2835, 1672, 1621, 1558, 1493, 1442, 1407, 1338,
1284, 1254, 1200, 1138, 1086, 1045, 977, 947, 799, 748, 708, 680, 634, 593, 550, 497; 1H NMR (DMSO-d6)
δ 8.41 (t, 1H, J = 5.9 Hz), 8.17 (d, 1H, J = 5.2 Hz), 8.09 (d, 1H, J = 8.6 Hz), 7.88 (d, 1H, J = 5.2 Hz),
7.59 (d, 2H, J = 8.5 Hz), 7.49–7.42 (m, 3H), 7.26 (d, 1H, J = 2.0 Hz), 6.87 (dd, 1H, J = 8.6, 2.1 Hz), 6.55 (d,
1H, J = 15.8 Hz), 4.67 (t, 2H, J = 6.8 Hz), 3.89 (s, 3H), 3.59 (q, 2H, J = 6.5 Hz), 2.99 (s, 3H); 13C NMR
(DMSO-d6) δ 165.53, 160.50, 142.90, 140.63, 137.83, 134.64, 133.99, 133.70, 129.29, 128.98, 128.48, 122.44,
122.38, 114.28, 112.26, 109.39, 93.50, 55.39, 43.34, 39.10, 23.07; ESI-MS: m/z 420.3 (M + 1)+; Anal. Calcd.
for C24H22ClN3O2: C, 68.65; H, 5.28; N, 10.01, found: C, 68.90; H, 5.11; N, 10.23.
(E)-N-(2-(7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-yl)ethyl)-3-(4-methoxyphenyl)acrylamide (5f)
CAD: 0.031 g of 4-methoxycinnamic acid; purification: Method A; yield: 0.046 g, (61%); mp 216–217.5 ◦C;
IR (ATR, ν/cm−1); 3212, 3102, 3040, 2993, 2973, 2940, 2919, 2840, 1667, 1620, 1604, 1558, 1514, 1474, 1443,
1409, 1382, 1338, 1306, 1283, 1254, 1229, 1198, 1173, 1138, 1096, 1033, 979, 949, 827, 801, 780, 731, 701,
684, 635, 592, 541, 521; 1H NMR (DMSO-d6) δ 8.31 (t, 1H, J = 5.9 Hz), 8.17 (d, 1H, J = 5.2 Hz), 8.09 (d,
1H, J = 8.6 Hz), 7.88 (d, 1H, J = 5.2 Hz), 7.51 (d, 2H, J = 8.8 Hz), 7.41 (d, 1H, J = 15.8 Hz), 7.27 (d, 1H,
J = 2.1 Hz), 6.97 (d, 2H, J = 8.8 Hz), 6.87 (dd, 1H, J = 8.6, 2.2 Hz), 6.40 (d, 1H, J = 15.8 Hz), 4.66 (t,
2H, J = 6.9 Hz), 3.90 (s, 3H), 3.79 (s, 3H), 3.58 (q, 2H, J = 6.6 Hz), 2.99 (s, 3H); 13C NMR (DMSO-d6) δ
166.04, 160.51, 160.41, 142.92, 140.63, 138.88, 137.81, 134.64, 129.17, 128.47, 127.30, 122.38, 119.15, 114.39,
114.26, 112.26, 109.43, 93.49, 55.38, 55.26, 43.42, 39.09, 23.06; ESI-MS: m/z 416.3 (M + 1)+; Anal. Calcd.
for C25H25N3O3: C, 72.27; H, 6.07; N, 10.11, found: C, 72.43; H, 6.32; N, 10.35.
3.1.6. General Procedure for the Synthesis of Harmicines 6a–h
A solution of CAD (0.20 mmol), DIEA (0.070 mL, 0.40 mmol) and HATU (0.077 g, 0.20 mmol) in
DCM (4 mL) was stirred at room temperature for 15 min, followed by the addition of amine 4 (0.049 g,
0.20 mmol). The resulting solution was stirred at room temperature for 1 h. The formed precipitate
was filtered off. After purification by column chromatography (DCM:MeOH = 85:15) and trituration
with diethyl ether, compounds 6a–h were obtained.
N-(2-((1-methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethyl)cinnamamide (6a)
CAD: 0.030 g of trans-cinnamic acid; yield: 0.045 g, (60%); mp 151.5 ◦C (decomp.); IR (ATR, ν/cm−1)
3994, 3908, 3838, 3784, 3718, 3656, 3424, 3222, 3060, 2972, 2932, 2874, 2768, 2372, 1898, 1720, 1630, 1574,
1544, 1486, 1450, 1392, 1332, 1280, 1234, 1174, 1110, 1056, 976, 812, 764, 684, 596; 1H NMR (DMSO-d6)
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δ 11.66 (s, 1H), 8.47 (t, 1H, J = 5.3 Hz,), 8.19 (d, 1H, J = 5.4 Hz), 8.11 (d, 1H, J = 8.7 Hz), 7.90 (d, 1H,
J = 5.4 Hz), 7.57 (d, 2H, J = 7.0 Hz), 7.48 (d, 1H, J = 15.8 Hz), 7.44–7.35 (m, 3H), 7.07 (d, 1H, J = 1.8 Hz),
6.91 (dd, 1H, J = 8.7, 2.0 Hz), 6.73 (d, 1H, J = 15.8 Hz), 4.20 (t, 2H, J = 5.4 Hz), 3.65 (q, 2H, 5.3 Hz),
2.77 (s, 3H); 13C NMR (DMSO-d6) δ 165.29, 159.52, 142.38, 140.70, 138.87, 136.37, 134.87, 134.45, 129.46,
128.92, 127.89, 127.52, 122.95, 122.02, 114.84, 112.25, 109.80, 95.39, 66.68, 38.51, 19.66; ESI-MS: m/z 372.2
(M + 1)+; Anal. Calcd. for C23H21N3O2: C, 74.37; H, 5.70; N, 11.31, found: C, 74.67; H, 5.75; N, 11.22.
(E)-3-(3-fluorophenyl)-N-(2-((1-methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethyl)acrylamide (6b)
CAD: 0.034 g of 3-fluorocinnamic acid; yield: 0.053 g, (67%); mp 210–212.5 ◦C; (ATR, ν/cm−1); 3954,
3908, 3838, 3784, 3718, 3656, 3256, 3070, 2940, 2866, 2812, 2370, 1872, 1778, 1720, 1670, 1630, 1580,
1486, 1444, 1344, 1250, 1178, 1110, 1060, 1028, 964, 852, 784, 670, 624, 594, 528; 1H NMR (DMSO-d6)
δ 11.47 (s, 1H), 8.47 (t, 1H, J = 5.5 Hz), 8.16 (d, 1H, J = 5.3 Hz), 8.08 (d, 1H, J = 8.7 Hz), 7.83 (d, 1H,
J = 5.3 Hz), 7.50–7.40 (m, 4H), 7.21 (ddd, 1H, J = 9.9, 3.9, 2.0 Hz), 7.05 (d, 1H, J = 2.1 Hz), 6.89 (dd, 1H,
J = 8.7, 2.2 Hz), 6.77 (d, 1H, J = 15.8 Hz), 4.19 (t, 2H, J = 5.4 Hz), 3.65 (q, 2H, J = 5.4 Hz), 2.74 (s, 3H);
13C NMR (DMSO-d6) δ 165.00, 162.44 (d, J = 243.8 Hz), 159.22, 141.97, 141.16, 137.59, 137.47, 137.42,
134.54, 130.88 (d, J = 8.4 Hz), 127.33, 123.65, 123.60, 122.72, 116.12 (d, J = 21.3 Hz), 115.00, 113.92 (d,
J = 21.8 Hz), 112.01, 109.42, 95.42, 66.62, 38.58, 20.17; ESI-MS: m/z 390.2 (M + 1)+; Anal. Calcd. for
C23H20FN3O2: C, 70.94; H, 5.18; N, 10.79, found: C, 70.83; H, 5.27; N, 10.99.
(E)-3-(3-bromophenyl)-N-(2-((1-methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethyl)acrylamide (6c)
CAD: 0.046 g of 3-bromocinnamic acid; yield: 0.043 g, (47%); mp 135–137.5 ◦C; IR (ATR, ν/cm−1) 3908,
3840, 3784, 3718, 3656, 3424, 3206, 3056, 2970, 2932, 2872, 2774, 2374, 1874, 1720, 1666, 1630, 1572, 1450,
1338, 1282, 1234, 1168, 1110, 1054, 972, 846, 786, 668, 602; 1H NMR (DMSO-d6) δ 11.48 (s, 1H), 8.44 (t,
1H, J = 5.5 Hz), 8.16 (d, 1H, J = 5.3 Hz), 8.08 (d, 1H, J = 8.7 Hz), 7.83 (d, 1H, J = 5.3 Hz), 7.79 (t, 1H,
J = 1.5 Hz), 7.60–7.55 (m, 2H), 7.45 (d, 1H, J = 15.8 Hz), 7.38 (t, 1H, J = 7.9 Hz), 7.05 (d, 1H, J = 2.1 Hz),
6.89 (dd, 1H, J = 8.7, 2.2 Hz), 6.78 (d, 1H, J = 15.8 Hz), 4.19 (t, 2H, J = 5.4 Hz), 3.65 (q, 2H, J = 5.4 Hz),
2.74 (s, 3H); 13C NMR (DMSO-d6) δ 164.93, 159.21, 141.97, 141.14, 137.47, 137.39, 137.22, 134.53, 131.97,
131.01, 130.04, 127.34, 126.40, 123.72, 122.72, 122.24, 114.99, 112.01, 109.42, 95.42, 66.62, 38.57, 20.16;
ESI-MS: m/z 450.1 (M + 1)+, 452.1 (M + 1)+; Anal. Calcd. for C23H20BrN3O22: C, 61.34; H, 4.48; N, 9.33,
C, 61.29; H, 4.67; N, 9.68.
(E)-3-(4-fluorophenyl)-N-(2-((1-methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethyl)acrylamide (6d)
CAD: 0.034 g of 4-fluorocinnamic acid; yield: 0.057 g, (73%); mp 199.5–200 ◦C; IR (ATR, ν/cm−1) 3952,
3908, 3840, 3786, 3718, 3634, 3572, 3430, 3248, 3072, 2940, 2866, 2812, 2600, 2366, 2050, 1872, 1720,
1668, 1630, 1576, 1508, 1456, 1344, 1278, 1230, 1178, 1110, 1030, 694, 796, 674, 626, 594, 506; 1H NMR
(DMSO-d6) δ 11.47 (s, 1H), 8.44 (t, 1H, J = 5.5 Hz), 8.16 (d, 1H, J = 5.3 Hz), 8.08 (d, 1H, J = 8.7 Hz),
7.83 (d, 1H, J = 5.3 Hz), 7.66–7.60 (m, 2H), 7.48 (d, 1H, J = 15.8 Hz), 7.29–7.22 (m, 2H), 7.05 (d, 1H,
J = 2.1 Hz), 6.89 (dd, 1H, J = 8.7, 2.2 Hz), 6.68 (d, 1H, J = 15.8 Hz), 4.19 (t, 2H, J = 5.5 Hz), 3.65 (q, 2H,
J = 5.4 Hz), 2.74 (s, 3H); 13C NMR (DMSO-d6) δ 165.23, 162.69 (d, J = 247.1 Hz), 159.23, 141.98, 141.16,
137.69, 137.43, 134.54, 131.51 (d, J = 2.7 Hz), 129.68 (d, J = 8.4 Hz), 127.34, 122.73, 121.92, 115.90 (d,
J = 21.7 Hz), 114.99, 112.01, 109.43, 95.42, 66.66, 38.55, 20.18; ESI-MS: m/z 390.2 (M + 1)+; Anal. Calcd.
for C23H20FN3O2: C, 70.94; H, 5.18; N, 10.79, found: C, 70.81; H, 5.39; N, 10.63.
(E)-3-(4-chlorophenyl)-N-(2-((1-methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethyl)acrylamide (6e)
CAD: 0.037 g of 4-chlorocinnamic acid; yield: 0.052 g, (64%); mp 230.5–234 ◦C; IR (ATR, ν/cm−1) 3908,
3838, 3784, 3716, 3656, 3268, 3044, 2942, 2880, 2774, 2372, 1720, 1662, 1626, 1560, 1488, 1450, 1330, 1284,
1234, 1168, 1102, 982, 874, 820, 740, 654, 588; 1H NMR (DMSO-d6) δ 11.68 (s, 1H), 8.49 (t, 1H, J = 5.5 Hz),
8.19 (d, 1H, J = 5.5 Hz), 8.11 (d, 1H, J = 8.7 Hz), 7.91 (d, 1H, J = 5.4 Hz), 7.60 (d, 2H, J = 8.5 Hz), 7.49–7.45
(m, 3H), 7.07 (d, 1H, J = 2.1 Hz), 6.91 (dd, 1H, J = 8.7, 2.2 Hz), 6.74 (d, 1H, J = 15.8 Hz), 4.20 (t, 2H,
J = 5.4 Hz), 3.65 (q, 2H, J = 5.4 Hz), 2.77 (s, 3H); 13C NMR (DMSO-d6) δ 165.09, 159.53, 142.40, 140.66,
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137.51, 136.29, 134.44, 133.87, 133.84, 129.22, 128.95, 127.92, 122.96, 122.83, 114.84, 112.26, 109.81, 95.38,
66.66, 38.53, 19.63; ESI-MS: m/z 390.2 (M + 1)+; Anal. Calcd. for C23H20ClN3O2: C, 68.06; H, 4.97; N,
10.35, found: C, 68.18; H, 4.84; N, 10.44.
(E)-3-(4-methoxyphenyl)-N-(2-((1-methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethyl)acrylamide (6f)
CAD: 0.036 g of 4-methoxycinnamic acid; yield: 0.051 g, (63%); mp 191–194.5 ◦C; (ATR, ν/cm−1); 3976,
3908, 3838, 3784, 3718, 3656, 3432, 3258, 3070, 2938, 2770, 2368, 2050, 1874, 1720, 1602, 1546, 1514, 1448,
1280, 1174, 1108, 1030, 984, 872, 828, 744, 714, 674, 588, 554, 518; 1H NMR (DMSO-d6) δ 11.46 (s, 1H),
8.35 (t, 1H, J = 5.5 Hz), 8.16 (d, 1H, J = 5.3 Hz), 8.07 (d, 1H, J = 8.7 Hz), 7.83 (d, 1H, J = 5.3 Hz), 7.52 (d,
2H, J = 8.8 Hz), 7.43 (d, 1H, J = 15.8 Hz), 7.05 (d, 1H, J = 2.1 Hz), 6.98 (d, 2H, J = 8.8 Hz), 6.89 (dd, 1H,
J = 8.7, 2.2 Hz), 6.58 (d, 1H, J = 15.8 Hz), 4.18 (t, 2H, J = 5.5 Hz), 3.79 (s, 3H), 3.64 (q, 2H, J = 5.4 Hz),
2.73 (s, 3H); 13C NMR (DMSO-d6) δ 165.60, 160.33, 159.23, 141.96, 141.18, 138.58, 137.48, 134.54, 129.10,
127.43, 127.31, 122.71, 119.52, 114.99, 114.38, 112.00, 109.41, 95.41, 66.70, 55.24, 38.50, 20.21; ESI-MS: m/z
402.2 (M + 1)+; Anal. Calcd. for C24H23N3O3: C, 71.80; H, 5.77; N, 10.47, found: C, C, 71.89; H, 5.54;
N, 10.36.
(E)-3-(2-fluorophenyl)-N-(2-((1-methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethyl)acrylamide (6g)
CAD: 0.034 g of 2-fluorocinnamic acid; yield: 0.061 g, (77%); mp 241.5 ◦C (decomp.); IR (ATR, ν/cm−1)
3838, 3784, 3716, 3636, 3570, 3252, 3066, 2942, 2864, 2818, 2600, 1866, 1668, 1630, 1576, 1486, 1456, 1344,
1278, 1234, 1180, 1100, 1060, 1022, 964, 850, 812, 750, 676, 626, 594; 1H NMR (DMSO-d6) δ 11.47 (s,
1H), 8.60 (t, 1H, J = 5.4 Hz), 8.15 (d, 1H, J = 5.3 Hz), 8.07 (d, 1H, J = 8.6 Hz), 7.81 (d, 1H, J = 5.3 Hz),
7.70–7.63 (m, 1H, 7.55 (d, 1H, J = 16.0 Hz), 7.48–7.39 (m, 1H), 7.28 (dd, 2H, J = 15.7, 8.3 Hz), 7.06 (d, 1H,
J = 2.0 Hz), 6.88 (dd, 1H, J = 8.7, 2.1 Hz), 6.84 (d, 1H, J = 16.0 Hz), 4.19 (t, 2H, J = 5.4 Hz), 3.65 (q, 2H,
J = 5.4 Hz), 2.73 (s, 3H); 13C NMR (DMSO-d6) δ 165.05, 160.45 (d, J = 250.4 Hz), 159.12, 141.87, 141.31,
137.72, 134.57, 131.35, 131.23, 129.08, 127.15, 124.97, 124.85 (d, J = 5.9 Hz), 122.65, 122.49 (d, J = 11.5 Hz),
116.08 (d, J = 21.8 Hz), 115.03, 111.93, 109.30, 95.44, 66.57, 38.61, 20.35; ESI-MS: m/z 390.3 (M + 1)+;
Anal. Calcd. for C23H20FN3O2: C, 70.94; H, 5.18; N, 10.79, found: C, 70.99; H, 4.97; N, 11.01.
(E)-2-methyl-N-(2-((1-methyl-9H-pyrido[3,4-b]indol-7-yl)oxy)ethyl)-3-phenylacrylamide (6h)
CAD: 0.033 g of α-methylcinnamic acid; yield: 0.047 g, (61%); mp 221.5–222.5 ◦C; (ATR, ν/cm−1) 3996,
3954, 3908, 3838, 3786, 3716, 3656, 3432, 3202, 3024, 2940, 2880, 2800, 2596, 2512, 2370, 1952, 1884,
1776, 1720, 1630, 1538, 1484, 1446, 1276, 1236, 1174, 1106, 1070, 972, 926, 850, 814, 760, 698, 664, 588,
516; 1H NMR (DMSO-d6) δ 11.52 (s, 1H), 8.33 (t, 1H, J = 5.3 Hz), 8.17 (d, 1H, J = 5.2 Hz), 8.09 (d, 1H,
J = 8.6 Hz), 7.85 (d, 1H, J = 5.1 Hz), 7.43–7.36 (m, 4H), 7.34–7.30 (m, 1H), 7.26 (s, 1H), 7.07 (s, 1H),
6.90 (d, 1H, J = 8.4 Hz), 4.22 (t, 2H, J = 5.2 Hz), 3.63 (q, J = 5.4 Hz, 2H), 2.75 (s, 3H), 2.04 (s, 3H);
13C NMR (DMSO-d6) δ 169.15, 159.42, 142.12, 141.01, 137.10, 136.02, 134.52, 132.50, 132.28, 129.21,
128.40, 127.70, 127.53, 122.79, 114.93, 112.08, 109.56, 95.47, 66.28, 38.96, 20.03, 14.29; ESI-MS: m/z 386.3
(M + 1)+; Anal. Calcd. for C24H23N3O2: C, 74.78; H, 6.01; N, 10.90, found: C, 74.99; H, 6.32; N, 10.73.
3.2. In Vitro Drug Sensitivity Assay against Erythrocytic Stages of P. falciparum
The antiplasmodial activity of harmicines 5 and 6 was evaluated against two laboratory P. falciparum
strains (3D7 – CQ-sensitive, and Dd2 – CQ-resistant), as previously described, using the histidine-rich
protein 2 (HRP2) assay [23,24]. Briefly, 96-well plates were pre-coated with the tested compounds in a
three-fold dilution before ring stage parasites were added in complete culture medium at a hematocrit
of 1.5% and a parasitemia of 0.05%. After three days of incubation at 37 ◦C, 5% CO2 and 5% oxygen,
plates were frozen until analyzed by HRP2-ELISA. All compounds were evaluated in duplicate in at
least two independent experiments. The IC50 was determined by nonlinear regression analysis of log
concentration–response curves using the drc package v0.9.0 of R v2.6.1 [22].
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3.3. In Vitro Activity against P. berghei Hepatic Stages
The in vitro activity of harmicines 5 and 6 against the liver stages of P. berghei infection was
assessed as previously described [25,26]. Briefly, Huh7 cells were routinely cultured in 1640
Roswell Park Memorial Institute (RPMI) medium supplemented with 10% (v/v) fetal bovine serum,
1% (v/v) glutamine, 1% (v/v) penicillin/streptomycin, 1% non-essential amino acids, and 10 mM
2-(4-(2-hydroxyethyl)piperazin-1-yl)ethanesulfonic acid (HEPES). For drug screening experiments,
Huh7 cells were seeded at 1 × 104 cell/well of a 96-well plate and incubated overnight at 37 ◦C with
5% CO2. Stock solutions of test compounds (10 mM) were prepared in DMSO and were serially diluted
in infection medium, i.e., culture medium supplemented with gentamicin (50 µg/mL) and amphotericin
B (0.8 µg/mL), in order to obtain the test concentrations. On the day of the infection, the culture medium
was replaced by serial dilutions of test compounds and incubated for 1 h at 37 ◦C with 5% CO2. Next,
1 × 104 firefly luciferase-expressing P. berghei sporozoites, freshly isolated from the salivary glands of
female infected Anopheles stephensi mosquitoes, were added to the cultures, plates were centrifuged at
1800× g for 5 min at room temperature and incubated at 37 ◦C with 5% CO2. To assess the effect of
each compound concentration on cell viability, cultures were incubated with Alamar Blue (Invitrogen,
Waltham, MA, USA) at 46 h post infection (hpi), according to the manufacturer’s recommendations.
The parasite load was then assessed by a bioluminescence assay (Biotium, Fremont, CA, USA), using a
multi-plate reader, Infinite M200 (Tecan, Männedorf, Switzerland). Nonlinear regression analysis was
employed to fit the normalized results of the dose–response curves, and IC50 values were determined
using GraphPad Prism 6.0 (GraphPad software, La Jolla, CA, USA).
3.4. In Vitro Cytotoxicity Assay
Cytotoxicity against a human cell line (HepG2) was evaluated using the neutral red assay [27].
In brief, human cells were seeded to a 96 well plate in complete culture medium, before on the following
day a serial dilution of the respective compound was added. After one day of incubation, cytotoxicity
was evaluated by the addition of Neutral Red, subsequent lysis of cells and the measurement of
absorbance in a plate reader. The IC50 was determined as for the in vitro drug assay against P. falciparum.
To assess the safety of a compound, SI was calculated as the fractional ratio between the IC50 values for
HepG2 and the P. falciparum 3D7 strain.
3.5. Molecular Dynamics Simulations
The starting point of our molecular dynamics simulations was a Pf Hsp90 N-terminal domain
structure obtained by X-ray crystallography from the Protein Data Bank (accession code 3K60).
Ligands (ADP and SO42−) were removed from the model and selected compounds were placed in
the ATP binding pocket, including harmine as a reference. Original crystal waters were removed
from the structure so that water molecules from the bulk solvent could diffuse into the protein during
equilibration and production MD runs. In order to parameterize the investigated ligands, geometry
optimization and RESP charge calculations were performed using the Gaussian 16 program [31]
at the HF/6–31G(d) level to be consistent with the employed GAFF force field, while the Pf Hsp90
protein was modeled using the AMBER ff14SB force field. Such protein complexes were solvated in a
truncated octahedral box of TIP3P water molecules spanning a 10-Å-thick buffer, neutralized by Na+
ions and submitted to geometry optimization in the AMBER 16 program [32] by employing periodic
boundary conditions in all directions. Optimized systems were gradually heated from 0 to 300 K
and equilibrated during 30 ps using NVT conditions, followed by productive and unconstrained MD
simulations of 300 ns by employing a time step of 2 fs at a constant pressure (1 atm) and temperature
(300 K), with the latter held constant using a Langevin thermostat with a collision frequency of
1 ps−1. Bonds involving hydrogen atoms were constrained using the SHAKE algorithm [33] while the
long-range electrostatic interactions were calculated employing the Particle Mesh Ewald method [34].
The nonbonded interactions were truncated at 10.0 Å.
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The binding free energies, ∆GBIND, of each ligand within the Pf Hsp90 ATP binding site were
calculated using the established MM-GBSA protocol [35,36] available in AmberTools16 [32], and in
line with our earlier reports [15,37,38]. MM-GBSA is a widely used method for binding free energy
calculations from snapshots of MD trajectory with an estimated standard error of 1–3 kcal mol−1 [36].
For that purpose, 1000 snapshots collected from the last 30 ns of the corresponding MD trajectories
were utilized. The calculated MM-GBSA binding free energies were decomposed into specific residue
contributions on a per-residue basis according to the established procedure [39,40]. This protocol
calculates contributions to ∆GBIND arising from each amino acid residue and identifies the nature of
the energy change in terms of interaction and solvation energies or entropic contributions.
4. Conclusions
In this paper, we have presented a synthesis of the amide-type harmicines, which is simpler
and more efficient than the synthesis of the triazole-type harmicines. This, in turn, offers significant
advantages in terms of the cost and availability of those compounds. We also investigated their
biological activities against erythrocytic and hepatic stages of Plasmodium, as well as against the HepG2
cell line and performed computational analysis in order to gain more insight into their binding to
Pf Hsp90. Amide-type harmicines exerted stronger antiplasmodial activities against the erythrocytic
stage of infection than their triazole counterparts. At the same time, their activities against hepatic
stages of P. berghei were not significant. Furthermore, N-harmicines displayed favorable selectivity
indices. Molecular dynamics simulations indicated that their binding to Pf Hsp90 might be crucial for
the inhibition of Plasmodium development. These results pave the way for the future enrichment of the
harmicines library, towards the establishment of a relevant QSAR model and the identification of a
lead compound for further development.
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compounds are available online.
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Young researcher’s career development project—training of doctoral students of the Croatian Science Foundation,
founded by the European Union through the European Social Fund.
Acknowledgments: T.T. and R.V. would like to thank the Zagreb University Computing Centre (SRCE) for
granting us the computational resources on the ISABELLA cluster.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
Abbreviations
ADP adenosine diphosphate
ATR attenuated total reflectance
Boc tert-butyloxycarbonyl
CAD cinnamic acid derivative
DCM dichloromethane
DIEA N,N-diisopropylethylamine
DMF N,N-dimethylformamide
ESI electrospray ionization
GAFF generalized Amber force field
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HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxidhexafluorophosphate
HEPES 2-(4-(2-hydroxyethyl)piperazin-1-yl)ethanesulfonic acid
HRP2 histidine-rich protein 2
HepG2 human liver hepatocellular carcinoma cell line
IC50 the concentration of the tested compound necessary for 50% growth inhibition
MD chloroquine-sensitive strain of P. falciparum
MM-GBSA molecular mechanics/generalized born surface area
MW microwave
Pf Dd2 chloroquine-resistant strain of P. falciparum
Pf Hsp90 P. falciparum heat shock protein 90
QSAR quantitative structure–activity relationship
RESP restrained electrostatic potential
SI selectivity index
TIP3P transferable intermolecular potential with 3 points
TMS tetramethylsilane
UATR universal attenuated total reflectance
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